Skip to main content
ENANTA PHARMACEUTICALS INC logo

ENANTA PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · ENTA ISIN · US29251M1062 LEI · 529900SSN4DODDQSN594 US Manufacturing
Filings indexed 812 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country US United States of America
Listing US ENTA

About ENANTA PHARMACEUTICALS INC

https://www.enanta.com/

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule drugs, with a focus on virology and immunology. The company utilizes a robust, chemistry-driven approach to create novel oral therapeutics for diseases with high unmet medical needs. Enanta has a significant track record of success, having developed protease inhibitors that are key components of treatment regimens for chronic hepatitis C virus (HCV) infection, which have cured over one million patients. Its current clinical pipeline is primarily focused on developing treatments for respiratory syncytial virus (RSV) and advancing its immunology programs for inflammatory diseases.

Recent filings

Filing Released Lang Actions
S-8 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
Regulatory Filings
2026-05-13 English
10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
Interim / Quarterly Report Q2 2026
2026-05-13 English
SCHEDULE 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)
Major Shareholding Notification
2026-03-26 English
8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a legal proceeding update regarding an appeal filed by Enanta Pharmaceuticals against Pfizer, including the scheduling of oral argument. There are no financial statements, earnings data, or detailed management discussion. The document is primarily an announcement of a legal event, not a full legal proceeding report or financial report. Given the nature of the content and the Form 8-K format, this fits best under Legal Proceedings Report (LTR). The document length is short and focused on a specific event, not a full report or announcement of a report publication.
2026-03-26 English
EFFECT - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
Regulatory Filings
2026-02-23 English
4 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
Director's Dealing
2026-02-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.